drugset / Trial / NCT05817708
A Study of Silmitasertib (CX-4945) in Healthy Subject
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I single center, open-label, parallel design in 30 subjects to evaluate safety and tolerability of CX-4945 200mg QD, 200 mg BID and 400mg BID doses (10 subjects in each regimen) for continuously 5 days in healthy subjects for dose selection.
Timeline
- Start
- 2022-11-28
- Primary completion
- 2023-03-23
- Completion
- 2023-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Silmitasertib | Small molecule | 200 mg | Oral |
| Subject | Silmitasertib | Small molecule | 400 mg | Oral |